GlassScriptPhysician profile
Colleen E St John
NPI 1316602147
$2,633.20
in general payments reported to CMS, 2019-2025
22 companies · $1,023 in 2025
The $1,023 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $620 · 2024: $991 · 2025: $1,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,633.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $433.05 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $357.79 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $244.98 | 2023-2025 | |
| Amgen INC. | $241.24 | 2023-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $207.97 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $182.25 | 2023-2025 | Gvoke Hypopen |
| Abbott Laboratories | $156.12 | 2023-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $115.10 | 2023-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $111.67 | 2023-2024 | |
| Boston Scientific Corporation | $107.49 | 2024 | Wavewriter Alpha Prime 16 |
| Glaxosmithkline, LLC. | $101.86 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Shield Therapeutics INC | $97.57 | 2023-2025 | Accrufer |
| Tris Pharma INC | $56.65 | 2024-2025 | Dyanavel Xr |
| Insulet Corporation | $46.88 | 2025 | Omnipod |
| Esperion Therapeutics, INC. | $41.38 | 2025 | Nexletol |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $35.65 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Neos Therapeutics, LP | $18.27 | 2023 | Adzenys Xr-Odt |
| Exact Sciences Corporation | $17.22 | 2023 | Cologuard Collection Kit |
| Lundbeck LLC | $16.80 | 2023 | Vyepti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2025 | Jardiance |
| Ibsa Pharma INC. | $14.50 | 2025 | Flector, Licart, Tirosint |
| Sumitomo Pharma America, INC. | $13.86 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen St John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.